TransMedics Group (TMDX) PT Raised to $40 at Oppenheimer
Get Alerts TMDX Hot Sheet
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 5
Join SI Premium – FREE
Oppenheimer analyst Suraj Kalia raised the price target on TransMedics Group (NASDAQ: TMDX) to $40.00 (from $25.00) while maintaining an Outperform rating.
The analyst commented, "After close (3/1), TransMedics announced FDA has communicated its intent to hold a Circulatory Systems Device Advisory Panel meeting on 4/6. While just outside the previously expected 1Q21 date, we're just glad to see it on the calendar, given all the competing COVID-19 priorities. While we don't yet see the meeting on the FDA's AdCom calendar, we'll be on the lookout for briefing documents (April 2nd). We'll also look for more on TMDX's 4Q call tomorrow night (Tuesday AMC). Raising our PT from $25 to $40, as the scheduling of the panel clears a near-term overhang on the story. Reiterate Outperform."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Travere Therapeutics (TVTX) PT Raised to $19 at H.C. Wainwright
- Meta Platforms Inc. (META) PT Raised to $562 at Rosenblatt, 'Squishy-ish guidance'
- Encompass Health Corp (EHC) PT Raised to $95 at Mizuho
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
AdCom, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!